Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
33.87
-0.17 (-0.50%)
At close: Mar 6, 2026, 4:00 PM EST
33.21
-0.66 (-1.95%)
After-hours: Mar 6, 2026, 4:22 PM EST

Corcept Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
761.41675.04482.38401.86365.98
Revenue Growth (YoY)
12.79%39.94%20.04%9.80%3.42%
Cost of Revenue
12.9810.886.485.395.28
Gross Profit
748.43664.16475.89396.47360.7
Selling, General & Admin
448.73280.32184.26152.85122.36
Research & Development
254.91246.89184.35130.99113.86
Other Operating Expenses
---28-
Total Operating Expenses
703.63527.21368.61311.84236.22
Operating Income
44.8136.95107.28112.63124.48
Interest Income
21.6724.5417.283.560.53
Total Non-Operating Income (Expense)
21.6724.5417.283.560.53
Pretax Income
66.46161.49124.56116.19125.01
Provision for Income Taxes
-33.1920.2818.4214.7712.49
Net Income
98.17139.73105.5101.29112.51
Net Income to Common
98.17139.73105.5101.29112.51
Net Income Growth
-29.74%32.45%4.15%-9.98%6.13%
Shares Outstanding (Basic)
104103104107116
Shares Outstanding (Diluted)
120113112116126
Shares Change (YoY)
5.73%1.55%-3.64%-7.94%1.42%
EPS (Basic)
0.951.351.020.950.97
EPS (Diluted)
0.821.230.940.870.89
EPS Growth
-33.33%30.85%8.05%-2.25%4.71%
Free Cash Flow
141.79196.12126.54119.91167.42
Free Cash Flow Growth
-27.71%54.99%5.53%-28.38%11.07%
Free Cash Flow Per Share
1.181.731.131.031.33
Gross Margin
98.30%98.39%98.66%98.66%98.56%
Operating Margin
5.88%20.29%22.24%28.03%34.01%
Profit Margin
13.09%20.92%22.00%25.24%30.74%
FCF Margin
18.62%29.05%26.23%29.84%45.75%
EBITDA
45.95137.75108.32113.89125.96
EBITDA Margin
6.03%20.41%22.46%28.34%34.42%
EBIT
44.8136.95107.28112.63124.48
EBIT Margin
5.88%20.29%22.24%28.03%34.01%
Effective Tax Rate
-49.94%12.56%14.79%12.71%9.99%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q